Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T22:53:07.969Z.
Calculation as of: 2026-10-06T22:53:07.969Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ae890bbb10947f62e3ed18d2c50ad40899bde2d85958fa14f481db4a948b3095
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$248.50M
EV/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$255.88M
EV/FCF Ratio
428.44x
TTM Avg
210.95x
3Y Avg
227.91x
5Y Avg
182.13x
Market Cap
$241.94M
EV/FCF Ratio
N/A
TTM Avg
894.08x
3Y Avg
541.45x
5Y Avg
277.55x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Upstream Bio, Inc. (UPB) | $249.79M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $248.50M | N/A | N/A | N/A | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $247.62M | N/A | N/A | N/A | N/A |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $247.27M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | 428.44x | 210.95x | 227.91x | 182.13x |
| AC Immune S.A. (ACIU)vs › | $256.47M | N/A | 4.58x | 4.76x | 4.76x |
| Lifecore Biomedical, Inc. (LFCR)vs › | $241.94M | N/A | 894.08x | 541.45x | 277.55x |
| Q32 Bio Inc. (QTTB)vs › | $241.39M | N/A | 9.08x | 9.08x | 9.08x |
| Quantum-Si incorporated (QSI)vs › | $241.34M | N/A | N/A | N/A | N/A |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
